Welcome to our dedicated page for Biodexa Pharmaceuticals Plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals PLC registers for resale 171,700,000 Ordinary Shares represented by 1,717 Depositary Shares, issuable upon exercise of pre-funded warrants from a December 2023 private placement. The prospectus states the Company will receive proceeds only if warrants are exercised for cash at an exercise price of $0.025 per share; otherwise all net proceeds will go to the selling shareholders. The Depositary Shares trade on NASDAQ under the symbol BDRX and each Depositary Share represents 100,000 Ordinary Shares. The prospectus discloses 324,156,808,922 Ordinary Shares outstanding as of March 12, 2026 and notes potential sales may occur in market, negotiated or brokered transactions.
Biodexa Pharmaceuticals PLC registers for resale up to 299,261,540,000 Ordinary Shares represented by 2,992,615 Depositary Shares (ADS) held or issuable to C/M Capital Master Fund, LP under an equity line Purchase Agreement.
The shares are being registered for resale by the Selling Shareholder; Biodexa is not selling shares here and will not receive proceeds from resale, although Biodexa may receive up to $35.0 million in aggregate gross proceeds if it elects to sell Depositary Shares to the Selling Shareholder under the Purchase Agreement. Each Depositary Share represents 100,000 Ordinary Shares. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.
Biodexa Pharmaceuticals PLC files a resale prospectus registering an aggregate of 109,800,000 Ordinary Shares, represented by 1,098 Depositary Shares, issuable upon exercise of Series D Warrants.
The prospectus states we will not receive proceeds from sales by the selling shareholders; proceeds will go to those sellers, though the company may receive proceeds if warrants are exercised for cash. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.
Biodexa Pharmaceuticals PLC is registering for resale up to 299,261,540,000 ordinary shares represented by 2,992,615 American Depositary Shares previously or potentially issued under a January 17, 2025 Purchase Agreement with C/M Capital Master Fund, LP.
This Post-Effective Amendment No. 2 updates the Form F-1 to include information from the Company’s Form 20-F for the year ended December 31, 2025 and updated selling shareholder disclosures. No new securities are being registered by this amendment; the prospectus covers resale of Depositary Shares issuable under the existing Equity Financing arrangement. The Company states it may receive up to $35.0 million gross under the Purchase Agreement depending on future sales, and that it will not receive proceeds from sales by the Selling Shareholder in this resale registration.
Biodexa Pharmaceuticals PLC files Post-Effective Amendment No. 2 to a Form F-1 to update its resale prospectus. The registration covers an aggregate of 943,400,000 Ordinary Shares represented by 9,434 American Depositary Shares, each ADS representing 100,000 Ordinary Shares. The company will not receive proceeds from resale by the selling shareholders; proceeds from any cash exercise of warrants would be received by the company.
This amendment updates information including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and selling shareholder details; no additional securities are being registered.
Biodexa Pharmaceuticals PLC filed Post-Effective Amendment No. 3 to a Form F-1 to update its registration statement and prospectus with 2025 annual report information and selling shareholder updates. The prospectus registers for resale 171,700,000 Ordinary Shares represented by 1,717 American Depositary Shares, issuable upon exercise of pre-funded warrants from a December 2023 private placement.
The company states it will receive no proceeds from these resale transactions and that all net proceeds will go to the selling shareholders; proceeds from cash exercises of the warrants would be payable to the company at an exercise price of $0.025 per Ordinary Share. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.